Valuation: Recursion Pharmaceuticals, Inc.

Market Cap 2.37B 2.12B 1.95B 1.77B 3.35B 222B 3.43B 23.31B 9.29B 119B 8.9B 8.71B 375B P/E 2026 *
-4.28x
P/E 2027 * -4.48x
Enterprise Value 1.81B 1.62B 1.49B 1.35B 2.56B 170B 2.63B 17.83B 7.11B 91.04B 6.81B 6.66B 287B EV / Sales 2026 *
45x
EV / Sales 2027 * 46.3x
Free-Float
98.26%
Yield 2026 *
-
Yield 2027 * -
1 day+8.10%
1 week-0.65%
Current month-5.58%
1 month-12.73%
3 months+18.17%
6 months+14.61%
Current year-6.97%
1 week 3.42
Extreme 3.42
4.01
1 month 3.42
Extreme 3.42
4.52
Current year 2.77
Extreme 2.77
5.24
1 year 2.77
Extreme 2.77
5.24
3 years 2.77
Extreme 2.77
15.74
5 years 2.77
Extreme 2.77
21.19
10 years 2.77
Extreme 2.77
42.81
Manager TitleAgeSince
Chief Executive Officer 43 01/01/2026
Director of Finance/CFO 48 20/11/2024
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 44 04/11/2013
Director/Board Member 62 04/11/2013
Director/Board Member 37 01/09/2016
Date Insider Type Main position Quantity % Market Cap. Importance
03/11/26 Sell

Founder

-40,000 0.0067%
02/11/26 Free

Chairman

156,658 0.0262%
06/10/26 Sell

Founder

-50,000 0.0093%
Change 5-day change 1-year change 3-year change Capi.($)
+8.10%-0.65%-17.64%-27.25% 2.19B
+2.24%+8.40%+58.47%+69.00% 66.7B
+4.66%+8.90%+16.93%+85.41% 56.88B
-0.60%+1.73%+24.32%+94.40% 56.53B
+2.55%+15.52%+30.43%+120.17% 46.49B
+2.58%+7.89%+32.49%+45.30% 44.8B
+4.09%+6.37%+228.06%+899.75% 41.59B
-0.47%+9.38%+27.53%+52.40% 35.35B
+3.80%-1.00%+98.16%+66.79% 33.29B
+1.48%+6.21%-38.80%+395.73% 25.1B
Average +2.84%+5.91%+45.99%+180.17% 41B
Weighted average by Cap. +2.32%+7.23%+53.36%+180.43%

Financials

2026 *2027 *
Net sales 40.32M 35.99M 33.12M 30.06M 56.96M 3.78B 58.37M 396M 158M 2.02B 151M 148M 6.37B 44.2M 39.45M 36.3M 32.95M 62.44M 4.14B 63.99M 434M 173M 2.22B 166M 162M 6.99B
Net income -479M -427M -393M -357M -676M -44.87B -693M -4.7B -1.87B -24.02B -1.8B -1.76B -75.66B -494M -441M -406M -368M -698M -46.33B -716M -4.86B -1.94B -24.81B -1.86B -1.82B -78.13B
Net Debt -558M -498M -458M -416M -788M -52.27B -807M -5.48B -2.18B -27.98B -2.09B -2.05B -88.13B -326M -291M -268M -243M -461M -30.59B -472M -3.21B -1.28B -16.37B -1.22B -1.2B -51.57B
Projected Income Statement - Annual - Recursion Pharmaceuticals, Inc.
Logo Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.
Employees
600
Date Price Change Volume
09/11/26 $3.805 +8.10% 20,352,503
06/11/26 $3.520 +0.57% 15,585,949
05/11/26 $3.500 -9.79% 25,416,509
04/11/26 $3.880 +5.43% 20,594,058
03/11/26 $3.680 -3.92% 20,780,778
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Recursion Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
3.805USD
Average target price
7.317USD
Spread / Average Target
+92.29%
  1. Stock Market
  2. Stocks
  3. RXRX Stock